Resveratrol and its metabolites elicit neuroprotection via high-affinity binding to the laminin receptor at low nanomolar concentrations.
Rayudu GopalakrishnaJennifer AguilarAndrew OhEmily LeeLucas HouTammy LeeEric XuJames NguyenWilliam J MackPublished in: FEBS letters (2024)
Resveratrol prevents various neurodegenerative diseases in animal models despite reaching only low nanomolar concentrations in the brain after oral administration. In this study, based on the quenching of intrinsic tryptophan fluorescence and molecular docking, we found that trans-resveratrol, its conjugates (glucuronide and sulfate), and dihydro-resveratrol (intestinal microbial metabolite) bind with high affinities (K d , 0.2-2 nm) to the peptide G palindromic sequence (near glycosaminoglycan-binding motif) of the 67-kDa laminin receptor (67LR). Preconditioning with low concentrations (0.01-10 nm) of these polyphenols, especially resveratrol-glucuronide, protected neuronal cells from death induced by serum withdrawal via activation of cAMP-mediated signaling pathways. This protection was prevented by a 67LR-blocking antibody, suggesting a role for this cell-surface receptor in neuroprotection by resveratrol metabolites.
Keyphrases
- molecular docking
- cerebral ischemia
- cell surface
- ms ms
- binding protein
- brain injury
- signaling pathway
- microbial community
- molecular dynamics simulations
- photodynamic therapy
- epithelial mesenchymal transition
- mouse model
- resting state
- blood brain barrier
- ischemia reperfusion injury
- oxidative stress
- pi k akt
- cancer therapy
- transcription factor
- endoplasmic reticulum stress